Board of Directors

Fate’s Board of Directors has founded and led the evolution of several of the most successful companies in the biotechnology space. The group has deep expertise in science, technology, drug development, finance, and strategy – all the tools necessary to help Fate emerge as an industry leader in the development and commercialization of programmed cellular immunotherapies.

William Rastetter, Ph.D.
Chairman
John Mendlein, Ph.D.
Vice Chairman
Timothy P. Coughlin
Board Member
Mark J. Enyedy
Board Member
4bio goes here
Robert S. Epstein, M.D.
Board Member
Amir Nashat, Ph.D.
Board Member
Scott Wolchko
President & CEO
8bio goes here